Asian Lionkang-KY monoclonal antibody ASLAN004 obtains positive results in proof-of-concept test for the treatment of acursions

recently, Aslam Pharmaceuticalscompany(http://announced that the company's development of the target IL-13 receptor alpha1 sub-base (IL-13 alpha1) monoclonal antibody ASLAN004, in the treatment of acur
sion dermatitis test(http://positive resultsAbout ASLAN004
ASLAN004 is a potential "first-in-class" humanized IL-13R alpha1 monoclonal antibodyIt blocks signaling of inflammatory cytokines IL-4 and IL-13 by combining with IL-13R alpha1IL-4 and IL-13 are the key cytokines that lead to allergic reactions and are also important targets for the treatment of asexual dermatitisbecause the expression range of IL-13R alpha1 is narrower than that of the IL-4 receptor, blocking IL-13R alpha1 may require lessdrug(http://dose and the number of subcutaneous injections, thus facilitating treatment for patientsIn a randomized double-blind, placebo-controlled clinical trial called MAD, patients with asexual dermatitis were treated with 3 different doses of ASLAN004 as of November 29 this year, six patients had been treated with the lowest dose of ASLAN004 results showed that in three patients who had been treated for at least one month, the eczema area and severity index (Eczema Area and Severity Index, EASI) scored 85 percent, 70 percent, and 59 percent, respectively, compared to baselines EASI continues to decline in the fourth week after treatment and is expected to achieve maximum results after 6-8 weeks of treatment